Relmada TherapeuticsRLMD
RLMD
About: Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Employees: 20
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
160% more call options, than puts
Call options by funds: $340K | Put options by funds: $131K
14.23% less ownership
Funds ownership: 42.07% [Q3] → 27.84% (-14.23%) [Q4]
30% less funds holding
Funds holding: 69 [Q3] → 48 (-21) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 20
75% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 28
89% less capital invested
Capital invested by funds: $41.3M [Q3] → $4.36M (-$36.9M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for RLMD.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB
Negative
Reuters
3 months ago
Relmada discontinues late-stage trials for depression drug, explores sale
Relmada Therapeutics said on Monday it would discontinue the two late-stage studies planned for the development of its depression drug and explore strategic alternatives including a sale.
Neutral
GlobeNewsWire
3 months ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Negative
Benzinga
3 months ago
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
On Wednesday, Relmada Therapeutics, Inc. RLMD announced a preplanned interim analysis of the Reliance II Phase 3 study.
Negative
Reuters
3 months ago
Relmada's depression drug unlikely to meet main trial goal, analysis shows
Relmada Therapeutics' depression treatment is "unlikely" to meet the main goal of a late-stage trial, it said on Wednesday, citing an independent data monitoring committee's analysis.
Neutral
GlobeNewsWire
3 months ago
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
The DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the development of REL-P11 for metabolic disease Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024 CORAL GABLES, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the pre-planned interim analysis of Reliance II, conducted by the Independent Data Monitoring Committee (DMC), indicated that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance.
Neutral
GlobeNewsWire
3 months ago
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ: RLMD) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Neutral
GlobeNewsWire
3 months ago
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight subjects With positive results, Phase 2a proof-of-concept study expected to begin in H1 2025 CORAL GABLES, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the initiation of dosing in a Phase 1 SAD study of REL-P11, an investigational agent for metabolic disease.
Neutral
Seeking Alpha
4 months ago
Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2024 Earnings Call November 7, 2024 4:30 PM ET Company Participants Tim McCarthy - Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Operator Hello and welcome to the Relmada Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for replay on the location website.
Neutral
PRNewsWire
4 months ago
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla. , Nov. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2024.
Charts implemented using Lightweight Charts™